Journal Article

Intravenous Tigecycline as Adjunctive or Alternative Therapy for Severe Refractory <i>Clostridium difficile</i> Infection

Bjorn L. Herpers, Bart Vlaminckx, Olaf Burkhardt, Harmjo Blom, Hazra S. Biemond-Moeniralam, Mathias Hornef, Tobias Welte and Edward J. Kuijper

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 48, issue 12, pages 1732-1735
Published in print June 2009 | ISSN: 1058-4838
Published online June 2009 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/599224
Intravenous Tigecycline as Adjunctive or Alternative Therapy for Severe Refractory Clostridium difficile Infection

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Clostridium difficile infection (CDI) has become more refractory to standard therapy. We describe 4 patients with severe refractory CDI who were successfully treated with tigecycline. Symptoms improved within 1 week. No relapses were observed. This favorable outcome suggests that tigecycline might be a useful alternative for treating severe refractory CDI.

Journal Article.  2192 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.